Sirna Therapeutics' P2P Acquisition

Sirna Therapeutics raised a round of funding on October 30, 2006. Investors include Merck & Co..

Sirna Therapeutics develops treatments based on RNAi technology for asthma, diabetes, hepatitis C, macular degeneration and Huntington's Disease.…

Articles about Sirna Therapeutics' P2P Acquisition: